http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Keon Uk Park ) (검색결과 96 건)
- 무료
- 기관 내 무료
- 유료
-
강혁주,김성욱,최석진,이중현,장재식,서영범,윤병구,박건욱,김성자,김용섭,강승완,이구,양창헌,이창우,김욱년,이광헌,서정일 동국대학교 의학연구소 2000 東國醫學 Vol.7 No.-
과립상 세포종은 Schwann 세포 기원으로 생각되며 인체에 비교적 드물게 발생한다. 과립상 세포종은 전신 어느 곳에서나 발견될 수 있으나 주로 혀, 구강, 피부 혹은 유방 등에서 호발하며 드물게 위장관에서 발견된다. 위장관에서는 식도에서 가장 호발하며 다음으로 위, 대장 순이다. 과립상 세포종은 대부분, 특히 위장관에서는 양성이며 소수의 악성 병변이 보고되었다. 이러한 이유와 함께 수술 전의 진단이 어렵기 때문에 과립상 세포종에 대한 근본적인 치료는 현재까지 외과적 절제술이다. 최근에 시도되는 치료방법들로는 내시경적 레이저 치료, 용종절제술, 내시경적 점막 절제술 등이 있다. 저자들은 상부 소화관 내시경검사를 시행하여 식도 과립상 세포종을 진단하고 내시경적 점막 절제술을 시행하여 합병증 없이 퇴원하여 현재 재발없이 경과 관찰중인 1례를 경험하였기에 보고하는 바이다. Granular cell tumors, which occur infrequently, are probably of Schwann cell origin. They can occur almost anywhere in the body but usually affect the tongue, oral cavity, skin, or breasts and are rarely found in the gastrointestinal tracts. The esophagus is the most frequent gastrointestinal site, followed by the stomach and the colon. Granular cell tumors are generally benign, especially in the gastrointestinal tract, some malignant lesions have been reported. For this reason, and also because preoperative diagnosis is difficult, the standard treatment for granular cell tumor has until now been surgical excision. In recent years, other therapeutic methods is endoscopic laser therapy (ELT), polypectiomy, endoscopic mucosal resection (EMR). We report a case of esophageal granular cell tumor which was diagnosed by an endoscopy and managed using an endoscopic mucosal resection without complication.
-
Park, Keon Uk 東國大學校醫學硏究所 2003 東國醫學 Vol.10 No.2
간암 특이발현 유전자의 대량 발굴을 위하여 RDA를 이용하는 subtracive library를 구축하였다. 간암 조직과 비교조직에서 발굴된 subtractive library 클론 각각 288개씩을 임의로 선택하여 이를 이용한 유전자칩을 제작하여 보다 정확한 검색을 시도하였다. 모두 50여종의 특이발현 유전자를 발굴하였으며, 간암조직에 특이적으로 발현된 유전자는 alpha fetoprotein, glypican-3, preferentially expressed antigen in melanoma (PRAME), fucosidase alpha, carcinoembryonic antigen (CEA), 그리고 topoisomerase Ⅱ 등이었다. 그 중 가장 많은 클론을 차지한 glypican 3 유전자에 대해서 좀 더 연구하였다. In situ hybridization 결과, glypican 3는 간암세포에 특이적으로 발현되고 있음을 알 수 있었다. 7종의 hepatocellular carcinoma와 hepatoblastoma 암세포주를 northern과 RT-PCR 법으로 검사한 결과 HepG2, Hep3B, SNU368, SNU398의 4종의 세포에서 glypican 3가 발현됨을 알아내었다. Glypican 3는 간암세포 표면에 특이적으로 발현되는 단백질이므로 간암의 진단이나 예후판정에 유용하게 이용될 수 있을 뿐 아니라 장차 glypican 3에 대한 항체 제작으로 간암의 면역치료요법의 표적물질이 될 수 있을 것으로 기대된다. To identify differentially expressed genes in human hepatocellular carcinoma (HCC), subtractive library by representational difference analysis (RDA) was constructed in hepatocellular carcinoma (HCC) and the corresponding background liver tissue. After TA cloning and random selection of subtractive library clones, they were used for microarray hybridization. After screening, more than 50 HCC specific gene fragments were identified, including alpha fetoprotein, glypican-3, preferentially expressed antigen in melanoma (PRAME), fucosidase alpha, carcinoembryonic antigen (CEA), and topoisomerase Ⅱ. We further characterized one of differentially expressed gene, glypican 3. In situ hybridization showed that glypican 3 was moderate to intensely expressed in HCC but not in normal hepatocytes. Northern blot and RT-PCR of glypican 3 gene in 7 hepatocellular/hepatoblastoma cell lines showed, HepG2 cells express high levels and Hep3B and SNU368 cells express moderate to low levels of glypican 3. Because glypican 3 is specifically expressed in hepatocellular carcinoma and is a cell surface protein, it can be a useful diagnostic marker and be a good target molecule for gene therapy or immunotherapy in hepatocellular carcinoma.
-
-
Anti-idiotype Therapeutic Cancer Vaccine for Lymphoma
Park, Keon Uk 東國大學校醫學硏究所 2007 東國醫學 Vol.14 No.1
환자 마다 다르게 표현되는 면역글로불린의 항원결정인자가 B형 비호지킨림프종의 적극적 면역요법의 좋은 표적이 될 수 있다. 이러한 항원결정인자를 표적으로 개발된 항암백신은 1상과 2상의 임상실험에서 상당히 고무적인 결과를 보였고 현재 3상의 임상시험이 진행 중이다. 이러한 항원결정인자를 이용한 방법이외에도 DNA, 수지상세포, 유전자 변이 종양세포를 이용한 항암백신의 개발이 현재 진행 중이고, 면역치료의 안전성과 효과가 충분히 향상된다면 항암화학요법과 병용 병용요법으로서 혹은 이를 대체할 수 있는 효과적인 치료방법으로서 이용 가능 할 것으로 보인다. The unique antigenic determinants (Idiotype [Id]) of the immunoglobulin expressed on a given B cell malignancy can serve as a tumor specific antigen for active immunotherapy. Therapeutic vaccines targeting the tumor specific idiotype have demonstrated promising results against lymphomas in phase I/II studies and are currently being evaluated in phase III randomized trials. Additional vaccine therapies being developed include those based on DNA, dendritic cells, gene modified tumor cells, It is hoped that immunotherapeutic agents, used in tandem or in combination, may in the future allow effective treatment of lymphoid malignancies and delay or even replace the need for conventional cytotoxic therapies.
-
-
박정배,성낙일,이준엽,허인경,김승민,남지형,이용국,최재혁,백진호,장태정,이종임,박건욱 동국대학교 의학연구소 2006 東國醫學 Vol.13 No.2
백화사설초는 한국과 중국에서 항암제로 이용되어온 약초이다. 이러한 백화사설초의 세포자멸사를 통한 항암 효과를 증명하기 위해 위암세포주인 SNU-719, 601, 668 각각에 백화사설초 메탄올 추출물로써 실험을 시행 하였다. 위암세포주 각각에 메탄올 추출물을 다양한 농도와 다양한 시간에 따라 실험 처치하여 세포 생존도를 측정하였다. 그리고 세포자멸사를 증명하기 위해 유세포분석을 통하여 subG1에 속하는 세포의 수를 계수하였고 Western blot 검사를 통해 caspase-3 enzyme의 발현을 조사하였다. SNU-719, 601 세포주에서는 메탄올추출물의 항암효과가 나타나지 않았고, SNU-668 세포주에서 항암효과가 나타났는데 메탄올 추출물 200과 400 ㎍/ml에서 농도에 비례하여 세포 생존도가 유의하게 감소하였다(0 ㎍/ml : 94.3土0.9%, 1 ㎍/ml : 95.8土0.8%, 5 ㎍/ml : 93.5土1.6%, 25 ㎍/ml : 95.3土2.0%, 50 ㎍/ml : 93.3土2.5%, 100 ㎍/ml : 93.5士3.8%, 200 ㎍/ml : 83.9土4.3%, 400 ㎍/ml : 72.8土8.4%). 100과 200 ㎍/ml, 200과 400 ㎍/ml 사이의 p-value는 각각 0.013, 0.005이었다. 그리고 메탄올 추출물 400 ㎍/ml을 SNU-668 세포주에 처리한 후 시간에 따른 세포 생존도를 조사한 결과 역시 시간의 증가에 따라 유의하게 감소하였다(0 hr. : 98.8土1.1%, 6 hr. ; 83.2土8.6%, 24 hr. : 37.6土8.3%, 48 hr. : 22.2土11.2%, p=0.019). 유세포분석상 subG1에 속하는 세포의 수는 농도와 시간에 비례하여 증가하였고 Western blot 검사상 caspase-3 proenzyme의 발현도 농도와 시간에 비례하여 감소하였다. 본 연구로 백화사설초의 메탄올 추출물이 위암세포주 SNU-668 세포자멸사에 효과가 있음이 증명되었다. 향후 백화사설초 메탄올 추출물의 성분분석과 세포자멸사 신호전달체계에 대한 연구를 통해 위암에 대한 새로운 항암물질 개발이 가능할 것으로 생각된다. Hedyotis diffusa has been used for cancer treatment in Korea and China. For the evaluation of anti-tumor activity through apoptosis, our experiments were performed with methanol extracts of Hedyotis diffusa on gastric cancer cell lines such as SNU-719, 601, 668. The cells were treated with various concentrations and periods of methanol extracts. Then, the cell viability was measured by trypan blue dye exclusion test. For the evaluation of apoptosis, we calculated the population of subG1 cells by the flow cytometry method, and examined the expression of caspase-3 by Western blot analysis. In SNU-719 and 601 cell lines, the anti-tumor activity of methanol extracts were not shown. However in SNU-668 cell lines, the anti-tumor activity was detected. The cell viability of SNU-668 was significantly decreased in a dose-dependent manner at 200 and 400 ㎍/ml of methanol extracts (0 ㎍/ml : 94.3±0.9%, 1 ㎍/ml : 95.8±0.8%, 5 ㎍/ml : 93.5±1.6%, 25 ㎍/ml : 95.3±2.0%, 50 ㎍/ml : 93.3±2.5%, 100 ㎍/ml : 93.5±3.8%, 200 ㎍/ml : 83.9±4.3%, 400 ㎍/ml : 72.8±8.4%). The p-values were 0.013 and 0.005 in between 100 ㎍/ml and 200 ㎍/ml, and 200 ㎍/ml and 400 ㎍/ml, respectively. The cell viability of SNU-668 was significantly decreased in a time-dependent manner as well (0 hr. : 98.8±1.1%, 6 hr. 83.2±8.6%, 24 hr. : 37.6±8.3%, 48 hr. : 22.2±11.2%, p=0.019). In the flow cytometry, the number of cells of subG1 population were increased in both dose-and time-dependent manners. In the Western blot analysis, caspase-3 proenzyme levels were decreased in both dose- and time-dependent manners as well. In conclusion, this study shows that methanol extracts of Hedyotis diffusa are effective on the apoptosis of SNU-668 gastric cancer cells. Therefore, through the analysis of components and the study of apoptotic signaling pathways of methanol extracts of Hedyotis diffusa, we could make a new drugs for the treatment of gastric cancer.
-
-
-
A case of adult Gaucher disease improved with the enzyme replacement therapy
( Myeong Soon Park ),( Won Young Jang ),( Mi Hwa Heo ),( Jin Young Kim ),( Keon Uk Park ),( Ki Young Kwon ),( Hong Suk Song ),( Young Rok Do ) 대한내과학회 2015 대한내과학회 추계학술대회 Vol.2015 No.1
Gaucher disease is an autosomal recessive, lysosomal storage disease caused by the deficiency of glucosylceramidase. Deficiency of this enzyme results in accumulation of glucoceramide in the macrophage and leads to hepatosplenomegaly, pancytopenia, bone damage and sometimes can be fatal. It is usually diagnosed in the first or second decade of life with the appearance of bone pain, splenomegaly and thrombocytopenia. There are several reports of Korean pediatric patient’s case with Gaucher disease instead ofrare adult patient. We report the case of a-40-years old man diagnosed Gaucher disease and successfully improved with the enzyme replacement therapy. A-40-years old man visited hospital with leukopenia and thrombocytopenia. On abdominal CT scan, his spleen was huge and mild hepatomegaly was shown. Initial laboratory test was perfomed including enzyme test, angiotensin-converting enzyme level was high. On bone marrow aspiration examination, there were no hematologic malignancies, just only few gaucher cellswith coarse cytoplasm and eccentric nucleus are found. Also, some collections of large cells with fibrillary cytoplasm were shown on bone marrow biopsy specimen, that suggests Gaucher disease. And he was performed hip MRI because of hip pain, there were marrow edema involving right SI joint. The patient received the enzyme replacement therapy with active enzyme using Cerezyme(imiglucerase), a recombinant form of glucosylceramidase. On enzyme replacement therapy, angiotensin-converting enzyme level was normalized, and spleen size was much decreased. His hip pain was improved with no other abnormal signal intensity on hip MRI. Gaucher disease should be considered in the differential diagnosis of adult patients with unexplained splenomegaly and bicytopenia. The early diagnosis of Gaucher disease would lead to safe and effective treatment with enzyme replacement, which can decrease morbidity.
-
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
